<DOC>
	<DOCNO>NCT01157039</DOCNO>
	<brief_summary>The investigator hypothesize glutamine significantly reduce incidence severity peripheral neuropathy patient receive oxaliplatin metastatic colorectal cancer , decrease need dose reduction oxaliplatin , impair oxaliplatin efficacy pharmacokinetics .</brief_summary>
	<brief_title>A Trial Glutamine Prevent Oxaliplatin Neurotoxicity Pharmacokinetic Analysis Oxaliplatin</brief_title>
	<detailed_description>This phase II , open-label , non randomize study oral glutamine administration evaluate oxaliplatin pharmacokinetics , prevent oxaliplatin neurotoxicity patient metastatic colorectal cancer .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Study Population : The target population patient metastatic colorectal adenocarcinoma sufficiently robust undergo least 3 cycle oxaliplatin base chemotherapy ( mFOLFOX XELOX ) Sampling Method : Probability Sample . Patients must hvae metastatic colorectal cancer ( stage IV ) Patients treat FOLFIRI regimen metastatic setting may eligible trial Patients must ≥ 18 year Patients must Eastern Cooperative Oncology Group ( EGOC ) performance status 0 2 . Patients must adequate renal function creatinine &lt; 1.5mg/dL creatinine clearance &gt; 45mL/min ; patient must adequate hepatic function bilirubin &lt; 1.5mg/dL AST ( normal range 014 U/L ) ALT ( normal range 049 U/L ) ; patient must adequate bone marrow function absolute neutrophil count ( ANC ) ≥ 1,500/цL platelet ≥ 100,000/цL hemoglobin ≥ 10g/d . Patients must willing able comply study protocol duration study . Patients must give write informed consent prior studyspecific screening procedure understand patient may withdraw consent time without prejudice . Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . The investigator request advise patient achieve adequate contraception Life expectancy longer 6 month Patients receive oxaliplatin previously Patients previous current diagnosis peripheral sensory neuropathy Patients test positive HIV Patients significant medical , psychiatric disorder , opinion investigator , exclude patient study compliance safety reason . Patients swallow History know allergy oxaliplatin platinum compound , 5FU , LV , glutamine ingredient formulation container Participation another clinical trial investigational drug within 30 day prior study screen . Pernicious anemia megaloblastic anemia vitamin B12 deficiency Patients concomitant treatment drugs/ingredients report potential activity prevent PSN Patients n't successfully complete local therapy previously treat CNS metastasis n't discontinue corticosteroid &gt; 4wks start chemotherapy . Patients asymptomatic brain mets . evidence midline shift CT/ MRI may enrol without initiation local therapy CNS mets . Repeat scan must preform &lt; 4wks ensure progression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>glutamine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>adverse effect</keyword>
</DOC>